STOCK TITAN

[Form 4] MARIMED INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), reported Section 16 transactions on 09/28/2025. 6,046 restricted stock units (RSUs) vested and were converted one-for-one into common shares. The issuer withheld 1,775 shares to satisfy tax-withholding obligations at a reported price of $0.143 per share. After these transactions the reporting person beneficially owned 731,938 shares. The vested RSUs were originally granted on 09/28/2024 and the remaining RSUs will vest in three equal installments on 03/28/2026, 09/28/2026 and 03/28/2027.

Ryan Crandall, Chief Commercial Officer di Marimed Inc. (MRMD), ha riportato operazioni di Sezione 16 il 28/09/2025. 6,046 RSU (restricted stock units) sono maturate e convertite una a una in azioni ordinarie. L'emittente ha trattenuto 1,775 azioni per soddisfare le obbligazioni di ritenuta fiscale a un prezzo riportato di $0,143 per azione. Dopo queste operazioni la persona informante deteneva beneficiamente 731,938 azioni. Le RSU maturate sono state originariamente concesse il 28/09/2024 e le RSU rimanenti matureranno in tre rate uguali il 28/03/2026, il 28/09/2026 e il 28/03/2027.

Ryan Crandall, Director Comercial de Marimed Inc. (MRMD), reportó operaciones de la Sección 16 el 28/09/2025. Se realizaron y convirtieron uno a uno 6,046 unidades de acciones restringidas (RSU). La entidad emisora retuvo 1,775 acciones para satisfacer las obligaciones de retención de impuestos a un precio reportado de $0,143 por acción. Después de estas transacciones, la persona informante poseía de manera beneficiosa 731,938 acciones. Las RSU adquiridas originalmente se concedieron el 28/09/2024 y las RSU restantes vencerán en tres cuotas iguales el 28/03/2026, el 28/09/2026 y el 28/03/2027.

Ryan Crandall, Marimed Inc.의 최고상업책임자(CCO)는 2025년 9월 28일 섹션 16 거래를 보고했습니다. 6,046개의 제한 주식 단위(RSUs)가 vesting되어 1대1로 보통주로 전환되었습니다. 발행사는 세금 원천징수 의무를 충족하기 위해 1,775주를 보유했고, 주당 표시된 가격은 $0.143였습니다. 이러한 거래 후 보고자은 유리하게 731,938주를 보유하게 되었습니다. 원래 2024년 9월 28일에 부여된 RSU는 vesting 되었고 남은 RSU는 2026년 3월 28일, 2026년 9월 28일, 2027년 3월 28일에 세 차례 등분으로 vesting 됩니다.

Ryan Crandall, directeur commercial de Marimed Inc. (MRMD), a signalé des transactions de la Section 16 le 28/09/2025. 6,046 unités d’actions restreintes (RSU) se sont vestées et ont été converties en actions ordinaires au compte une fois. L’émetteur a retenu 1,775 actions pour satisfaire les obligations de retenue d’impôt à un prix déclaré de $0,143 par action. Après ces opérations, la personne sous rapport détenait bénéficiellement 731,938 actions. Les RSU accordées initialement le 28/09/2024 se sont vestées et les RSU restants seront versés en trois tranches égales les 28/03/2026, 28/09/2026 et 28/03/2027.

Ryan Crandall, Chief Commercial Officer von Marimed Inc. (MRMD), meldete Transaktionen gemäß Section 16 am 28.09.2025. 6.046 RSUs (restricted stock units) veretzten und eins zu eins in Stammaktien umgewandelt. Der Emittent behielt 1.775 Aktien ein, um die Steuerabzugsverpflichtungen zu erfüllen, zu einem berichteten Preis von $0,143 pro Aktie. Nach diesen Transaktionen hielt die berichtende Person vorteilhaft 731.938 Aktien. Die ursprüngliche Zuteilung der RSUs erfolgte am 28.09.2024; die verbleibenden RSUs vesten in drei gleichen Raten am 28.03.2026, 28.09.2026 und 28.03.2027.

Ryan Crandall، المدير التجاري في Marimed Inc. (MRMD)، أبلغ عن معاملات القسم 16 في 28/09/2025. تم vesting لـ 6,046 وحدات أسهم مقيدة (RSUs) وتحويلها واحدًا لواحد إلى أسهم عادية. قامت المُصدِر باحتجاز 1,775 سهمًا لتلبية التزامات حجز الضريبة عند سعر مُبلغ عنه قدره $0.143 للسهم. بعد هذه المعاملات، امتلك الشخص المبلغ عنه بشكل مستفيد 731,938 سهمًا. تم منح RSUs في الأصل في 28/09/2024 وستتم vesting RSUs المتبقية على ثلاث دفعات متساوية في 28/03/2026 و28/09/2026 و28/03/2027.

Ryan Crandall,Marimed Inc.(MRMD)的首席商务官,在2025年9月28日披露了第16条交易。6,046份受限股票单位(RSU)已归属并按一对一转换为普通股。发行人为满足税收代扣义务,扣留了1,775股,按披露价格每股为$0.143。交易完成后,披露人实际持有731,938股。原始授予日期为2024年9月28日,剩余的RSU将分三次等额归属,分别在2026年3月28日、2026年9月28日和2027年3月28日归属。

Positive
  • RSU vesting demonstrates compensation alignment: 6,046 RSUs converted to shares
  • Significant insider ownership remains: reporting person beneficially owns 731,938 shares
  • Transparent vesting schedule disclosed for remaining RSUs with specific future dates
Negative
  • Shares withheld for taxes reduced the net new shares by 1,775
  • No open-market purchases reported; transaction reflects compensation, not additional direct investment

Insights

TL;DR: Insider compensation converted to shares; modest dilution from tax withholding, ownership remains substantial.

The filing shows routine equity compensation vesting rather than an open-market purchase or sale. The conversion of 6,046 RSUs to shares increases outstanding insider-held shares nominally while the issuer withheld 1,775 shares for taxes at $0.143 per share, which is an administrative net reduction to the insider's holding. The reporting person still holds 731,938 shares, indicating meaningful insider alignment with shareholders. No cash sale or outside disposition is reported.

TL;DR: Standard executive award vesting with scheduled future vesting; nothing indicating governance concerns.

This Form 4 documents scheduled vesting of RSUs granted a year earlier and confirms tax withholding practices. The disclosure that remaining RSUs vest in three future installments is explicit, supporting predictable executive compensation timing. There are no unusual transactions, loans, or related-party disposals disclosed that would raise governance flags.

Ryan Crandall, Chief Commercial Officer di Marimed Inc. (MRMD), ha riportato operazioni di Sezione 16 il 28/09/2025. 6,046 RSU (restricted stock units) sono maturate e convertite una a una in azioni ordinarie. L'emittente ha trattenuto 1,775 azioni per soddisfare le obbligazioni di ritenuta fiscale a un prezzo riportato di $0,143 per azione. Dopo queste operazioni la persona informante deteneva beneficiamente 731,938 azioni. Le RSU maturate sono state originariamente concesse il 28/09/2024 e le RSU rimanenti matureranno in tre rate uguali il 28/03/2026, il 28/09/2026 e il 28/03/2027.

Ryan Crandall, Director Comercial de Marimed Inc. (MRMD), reportó operaciones de la Sección 16 el 28/09/2025. Se realizaron y convirtieron uno a uno 6,046 unidades de acciones restringidas (RSU). La entidad emisora retuvo 1,775 acciones para satisfacer las obligaciones de retención de impuestos a un precio reportado de $0,143 por acción. Después de estas transacciones, la persona informante poseía de manera beneficiosa 731,938 acciones. Las RSU adquiridas originalmente se concedieron el 28/09/2024 y las RSU restantes vencerán en tres cuotas iguales el 28/03/2026, el 28/09/2026 y el 28/03/2027.

Ryan Crandall, Marimed Inc.의 최고상업책임자(CCO)는 2025년 9월 28일 섹션 16 거래를 보고했습니다. 6,046개의 제한 주식 단위(RSUs)가 vesting되어 1대1로 보통주로 전환되었습니다. 발행사는 세금 원천징수 의무를 충족하기 위해 1,775주를 보유했고, 주당 표시된 가격은 $0.143였습니다. 이러한 거래 후 보고자은 유리하게 731,938주를 보유하게 되었습니다. 원래 2024년 9월 28일에 부여된 RSU는 vesting 되었고 남은 RSU는 2026년 3월 28일, 2026년 9월 28일, 2027년 3월 28일에 세 차례 등분으로 vesting 됩니다.

Ryan Crandall, directeur commercial de Marimed Inc. (MRMD), a signalé des transactions de la Section 16 le 28/09/2025. 6,046 unités d’actions restreintes (RSU) se sont vestées et ont été converties en actions ordinaires au compte une fois. L’émetteur a retenu 1,775 actions pour satisfaire les obligations de retenue d’impôt à un prix déclaré de $0,143 par action. Après ces opérations, la personne sous rapport détenait bénéficiellement 731,938 actions. Les RSU accordées initialement le 28/09/2024 se sont vestées et les RSU restants seront versés en trois tranches égales les 28/03/2026, 28/09/2026 et 28/03/2027.

Ryan Crandall, Chief Commercial Officer von Marimed Inc. (MRMD), meldete Transaktionen gemäß Section 16 am 28.09.2025. 6.046 RSUs (restricted stock units) veretzten und eins zu eins in Stammaktien umgewandelt. Der Emittent behielt 1.775 Aktien ein, um die Steuerabzugsverpflichtungen zu erfüllen, zu einem berichteten Preis von $0,143 pro Aktie. Nach diesen Transaktionen hielt die berichtende Person vorteilhaft 731.938 Aktien. Die ursprüngliche Zuteilung der RSUs erfolgte am 28.09.2024; die verbleibenden RSUs vesten in drei gleichen Raten am 28.03.2026, 28.09.2026 und 28.03.2027.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Crandall Ryan

(Last) (First) (Middle)
10 OCEANA WAY, 2ND FLOOR

(Street)
NORWOOD MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 09/28/2025 M 6,046 A $0(1) 733,713 D
Common stock 09/28/2025 F 1,775(2) D $0.143 731,938 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 09/28/2025 M 6,046 (3) (3) Common Stock, par value $.001 per share 6,046 $0 18,140 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These RSUs were granted on September 28, 2024; the remaining RSUs will vest in three equal installments on each of March 28, 2026, September 28, 2026 and March 28, 2027 in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Ryan Crandall 09/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MRMD insider Ryan Crandall report on Form 4?

The report shows 6,046 RSUs vested on 09/28/2025, converting one-for-one to common shares, with 1,775 shares withheld for taxes.

How many MRMD shares does Ryan Crandall beneficially own after the transactions?

After the reported transactions the reporting person beneficially owns 731,938 shares.

Were any shares sold in the transactions reported on the Form 4?

No open-market sales were reported; the transactions are vesting of RSUs and tax-withholding disposals.

When will the remaining RSUs vest for Ryan Crandall?

The remaining RSUs will vest in three equal installments on 03/28/2026, 09/28/2026 and 03/28/2027.

What price is shown in the Form 4 for the withheld shares?

The Form 4 shows a price of $0.143 associated with the 1,775 shares withheld to satisfy tax obligations.
Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood